Feed BRTX
BR

BioRestorative Therapies, Inc.

BRTX · NASDAQ

$2.69 +0.03% (+$0.00)
1M -36.85%
Market Cap $3.72M
P/E Ratio -
Div. Yield -
ROE 423.84%

Bulios Fair Price

$2.4

10.8% downside

Trenutna cena

$2.69

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica BRTX trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
2/9
Valuation
50 /100
Fair
P/B 1.23x
P/S 10.38x
EV/EBITDA N/A
Growth
78 /100
Growing
Book val. growth 67.39%
Rev. growth 44.27%
FCF growth N/A
Profitability
20 /100
Weak
Net margin 3,089.55%
Op. margin 3,975.00%
FCF margin 3,324.57%
Quality
1 /100
Poor
ROE 423.84%
ROA 238.27%
Asset turnover 0.08x
Debt
100 /100
Low
Current ratio 2.35x
Debt/Equity 0.01x
Net debt/EBITDA N/A
Stability
38 /100
Moderate
Rev. volatility 99.06%
EPS volatility 46.71%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o BRTX
Online

O podjetju

BioRestorative Therapies, Inc. (BRTX) is a biotechnology company focusing on the development and commercialization of therapeutic therapies in the field of regenerative medicine. The company specializes in developing therapeutic products that utilize patients' own cells and tissues to support the healing and regeneration of damaged tissues. BioRestorative Therapies targets the treatment of various health conditions, including orthopedic disorders, degenerative diseases, and more. With the growing interest in regenerative medicine and the need for new treatment approaches, BioRestorative Therapies, Inc. has the potential for sustained growth. BioRestorative Therapies, Inc. (BRTX) shares might be an interesting choice for investors seeking involvement in the biotechnology and regenerative medicine industry.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Katharyn Field

Employees

14

Headquarters

Melville

Prihajajoči dogodki

22 SEP.

Earnings

Upcoming earnings report

1d
18 NOV.

Earnings

Upcoming earnings report

58d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.